tiprankstipranks
Cynata Therapeutics Limited (CYYNF)
OTHER OTC:CYYNF

Cynata Therapeutics Limited (CYYNF) Stock Price & Analysis

3 Followers

CYYNF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.07 - $0.24
Previous Close$0.11
Volume220.00
Average Volume (3M)220.00
Market Cap
$32.00M
Enterprise Value$16.12M
Total Cash (Recent Filing)AU$23.80M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)
Beta-0.13
Aug 22, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding179,631,786
10 Day Avg. Volume0
30 Day Avg. Volume220
Standard Deviation0.21
R-Squared0.03
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

3.72%0.00%0.00%96.28%
0.00% Other Institutional Investors
96.28% Public Companies and
Individual Investors

CYYNF FAQ

What was Cynata Therapeutics Limited’s price range in the past 12 months?
Cynata Therapeutics Limited lowest stock price was $0.07 and its highest was $0.24 in the past 12 months.
    What is Cynata Therapeutics Limited’s market cap?
    Currently, no data Available
    When is Cynata Therapeutics Limited’s upcoming earnings report date?
    Cynata Therapeutics Limited’s upcoming earnings report date is Aug 22, 2024 which is in 89 days.
      How were Cynata Therapeutics Limited’s earnings last quarter?
      Cynata Therapeutics Limited released its earnings results on Feb 23, 2024. The company reported -$0.017 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.017.
        Is Cynata Therapeutics Limited overvalued?
        According to Wall Street analysts Cynata Therapeutics Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Cynata Therapeutics Limited pay dividends?
          Cynata Therapeutics Limited does not currently pay dividends.
          What is Cynata Therapeutics Limited’s EPS estimate?
          Cynata Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Cynata Therapeutics Limited have?
          Cynata Therapeutics Limited has 179,631,790 shares outstanding.
            What happened to Cynata Therapeutics Limited’s price movement after its last earnings report?
            Cynata Therapeutics Limited reported an EPS of -$0.017 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Cynata Therapeutics Limited?
              Currently, no hedge funds are holding shares in CYYNF
              ---

              Cynata Therapeutics Limited Stock Smart Score

              6
              Neutral
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Fundamentals

              Return on Equity
              -85.62%
              Trailing 12-Months
              Asset Growth
              -34.05%
              Trailing 12-Months

              Company Description

              Cynata Therapeutics Limited

              Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which has branded Cymerus.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              CytoDyn
              Cytokinetics
              Atara Biotherapeutics
              Editas Medicine
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis